Regena-Vue, Inc. is a development stage company located in Oklahoma City, and incorporated in Delaware. The company was founded in August 2004, to commercialize botanical drug technology for treatment of Age-Related Macular Degeneration ("AMD" or "ARMD"). The company is supported by top-tier institutions, including partnerships listed below.
Primavera both licenses the rights to manufacture and market its proprietary compounds and products to qualified parties for specific market segments and geographical territories and markets them itself through licensed distributors. The company does not maintain manufacturing facilities of its own and maintains relationships, for its production, testing, package design, and customer service requirements with various typically larger contractors specializing in these functions. Primavera's patents, issued and pending, generally cover inventions originated by its management and assigned to the Company. Its Federal and State registrations are pursued, obtained and maintained by the Company. The Company's products are also tested, manufactured, advertised, and marketed in compliance with applicable FDA regulations and guidelines in the U.S and equivalent agency requirements in other jurisdictions in which they are sold. Primavera's products do not contain DEET (n,n diethyl-m-toluamide) or other non-natural compounds which the Company believes may pose significant health hazards or environmental risks in ordinary use. Thus much of its research is devoted to developing effective, cosmetically attractive and "user friendly" means of delivering personal and pet care benefits without such risk factors. The most prominently marketed product group developed by the company to date is a cosmetically attractive lotion combining sunscreens, in a range of Sun Protections Factors (SPF's) , moisturizing skin conditioners, and natural insect repellents in a single convenient "outdoor protection lotion". A version of this product line, under license from Primavera, has been publicly described by its distributor, one of the world's leading direct marketers, as the "most successful new productg inroduction in [its] history" and has been the recipient of numerous personal care industry awards for merit. The company has in various stages of development, testing and (EPA) regisgtration, a wide range of new skin care, hair care, petcare and other-use products, principally combining its proprietary, natural insect repellency technology and other efficacies. It believes itself to be the U.S leader in this specialized field. Primavera is a private, family-owned company, owned and managed by its founders.
Epitome Pharmaceuticals identifies, develops and licenses promising medications. Investigation is conducted by reading the scientific literature, discussing anomalies and questions with leaders in their fields, and by statistical reanalysis of published data. Once a remedy has been identified and intellectual property rights secured, we proceed to advance the development of the medication. We clarify regulatory issues through close cooperation with regulatory agencies. Based on our research and the prospects for a specific medication, we may file an IND and initiate Phase I or Phase II trials. Ultimately, Epitome Pharmaceuticals seeks to license its intellectual property to a partner (or partners) with the resources and capabilities to complete clinical trials, secure regulatory approval and bring a product to market most effectively.
At TSR Custom Embroidery and Screen Printing, we have provided wholesale embroidery, tackle twill, screen printing and in house digitizing to companies, teams, clubs, contract suppliers and ad specialty companies for over 20 years. As a full service ad specialties company, TSR wants to provide you with the best quality designs, embroidery and screen printing in a timely fashion with competative prices to meet your clients needs. The company has grown from this humble beginning to a nationally recognized force in the embroidery industry serving customers all over the United States. We are proud to have Barudan multi-head computerized embroidery machines in our production area, with a combined total of 33 heads. We are also very proud of our digitizing department that not only produces the designs neccessary to operate our machines, but also furnishes computer designs disk to other embroidery companies located throughout the U.S. As a family owned corporation, TSR combines state-of-the-art systems with old fashioned values centered around you, our customer. It is our philosophy to keep every promise and to meet or exceed all customer expectations. Just check out our wholesale pricing & screen printing pricing ; and you'll be surprised how great a deal we can make for you.
NeuroSystec Corporation feels very strongly about personal privacy rights. Any information of a personal nature that we collect about our clients or patients will be held in the strictest confidence. Only statistics and medical knowledge or information gained from our research that is not tied directly to the identity of specific persons will be released or shared with the medical community or our partners and collaborators without that person's knowledge. If we feel that a partner or collaborator of ours has medical information or a treatment that would benefit a client or a patient of ours, we will seek permission to share the information with that party before we do so. We feel very strongly about your privacy as well as our own. If we request an email address from you, we will not share or sell your email address, or any piece of personal information, without obtaining your permission in advance. We may periodically send email to notify clients or patients about important product information, but this will only be on an opt-in basis where you have the ability to decline to receive such notifications. From time to time our web servers may place "cookies" on your computer. Our cookies will only be read back by our servers and are for internal use only (for instance, to help you navigate our site, or fill in a form or questionnaire on our site more efficiently). They are never used to collect information about you. If you have questions concerning our privacy policy, please don't hesitate to contact us.
Rhinopharma Ltd is a newly formed company dedicated to finding new drug treatments for rhinitis and other respiratory diseases. In the first phase of research strategy Rhinopharma is searching for new drugs for allergic rhinitis that can be rapidly brought to clinical trial. A longer term strategic goal of the company is to develop a range of therapeutic agents based on novel polysaccharide molecules. These molecules are biological "non-stick" agents with potential applications in inflammation, cell adhesion and tissue growth. The company plans to initially commercialize one such molecule as an anti-inflammatory agent for the treatment of allergic rhinitis in a relatively easy path to market, and then progress to research and development of agents based on active fragments of heparin and related natural and synthetic compounds. The company has access to powerful new synthetic and analytical chemical techniques which it will apply to modify heparin, and related molecules, to produce novel agents for the treatment of respiratory allergies, asthma and other inflammatory diseases. In the longer term, therapeutic applications also exist for arthritis, skin and bladder diseases. As part of this strategy the company also aims to exploit anti-adhesion molecules produced by echinoderms (starfish and related organisms) as improved therapeutic agents.
ProCertus BioPharm, Inc. is an oncology-based pharmaceutical company established in 1997 with administrative and research facilities located in Madison, Wisconsin. The ProCertus mission is: To discover and develop innovative pharmaceutical products that protect cancer patients against the side effects of their therapy. The Company holds exclusive world-wide license to a breakthrough technology platform based upon the research and development activities of Dr. William E. Fahl, a world-recognized expert in cancer research with the McArdle Laboratory for Cancer Research at the University of Wisconsin-Madison. Based on a common technology platform, the Company has developed DermX, ProDermaCelÔ and OralX in parallel through animal proof of concept, and will advance all three product candidates to safety and efficacy studies in normal human subjects and cancer patients. ProCertus management believes that ProDermaCelÔ, DermX, and OralX will fundamentally change the quality of life for cancer patients.
Acretia is a drug development company that in-licenses exciting product candidates from leading medical institutions and establishes partnerships with biotechnology and pharmaceutical companies under which we collectively strive to validate the clinical utility of our products then seek approval. We are currently advancing the development of a product for hyper-proliferative inflammatory diseases of the skin and a women's health product for management of precancerous lesions of the anogenital tract.
Minster Pharmaceuticals is a drug development company specialising in compounds for the treatment of neurological and psychiatric conditions. The company, whose management has extensive scientific, commercial, regulatory and project management experience, has acquired from GlaxoSmithKline the worldwide development rights to two compounds, tonabersat and sabcomeline.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory